These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 37667195)
41. Prevalence of SARS-CoV-2 antibodies among nurses: A systematic review and meta-analysis. He S; Hecimovic A; Matijasevic V; Mai HT; Heslop L; Foster J; Alexander KE; Pal N; Alexandrou E; Davidson PM; Frost SA J Clin Nurs; 2022 Jun; 31(11-12):1557-1569. PubMed ID: 34570947 [TBL] [Abstract][Full Text] [Related]
42. Effect of anti-inflammatory drugs on the storm of inflammatory factors in respiratory tract infection caused by SARS-CoV-2: an updated meta-analysis. Qin Z; Li Y; Sun W; Lu Y; Zhang N; Yang R; Liu Y; Tang L; Liu Q Front Public Health; 2023; 11():1198987. PubMed ID: 37920591 [TBL] [Abstract][Full Text] [Related]
43. The Vaccine Efficacy Against the SARS-CoV-2 Omicron: A Systemic Review and Meta-Analysis. Zou Y; Huang D; Jiang Q; Guo Y; Chen C Front Public Health; 2022; 10():940956. PubMed ID: 35910897 [TBL] [Abstract][Full Text] [Related]
45. Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis. Dai C; Dong ZY; Wang YN; Huang YH; Jiang M Rev Esp Enferm Dig; 2023 Jun; 115(6):306-314. PubMed ID: 36353949 [TBL] [Abstract][Full Text] [Related]
46. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis. Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570 [TBL] [Abstract][Full Text] [Related]
47. Postvaccination SARS-CoV-2 infection among healthcare workers: A systematic review and meta-analysis. Chandan S; Khan SR; Deliwala S; Mohan BP; Ramai D; Chandan OC; Facciorusso A J Med Virol; 2022 Apr; 94(4):1428-1441. PubMed ID: 34783055 [TBL] [Abstract][Full Text] [Related]
48. SARS-CoV-2 Breakthrough Infections after introduction of 4 COVID-19 Vaccines, South Korea, 2021. Yi S; Choe YJ; Kim J; Kim YY; Kim RK; Jang EJ; Lim DS; Byeon HR; Lee S; Park E; Kim SJ; Park YJ Emerg Infect Dis; 2022 Mar; 28(3):753-756. PubMed ID: 35202529 [TBL] [Abstract][Full Text] [Related]
49. Long term effectiveness of inactivated vaccine BBIBP-CorV (Vero Cells) against COVID-19 associated severe and critical hospitalization in Morocco. Belayachi J; Obtel M; Mhayi A; Razine R; Abouqal R PLoS One; 2022; 17(12):e0278546. PubMed ID: 36477077 [TBL] [Abstract][Full Text] [Related]
50. Comparison of telecardiac rehabilitation with centre-based cardiac rehabilitation and usual care: a protocol for systematic review including a meta-analysis. Bashir Z; Shahab A; Imran H Open Heart; 2022 Aug; 9(2):. PubMed ID: 35961694 [TBL] [Abstract][Full Text] [Related]
51. The effect of COVID-19 mRNA vaccines against postvaccination laboratory-confirmed SARS-CoV-2 infection, symptomatic COVID-19 infection, hospitalization, and mortality rate: a systematic review and meta-analysis. Baradaran HR; Dehghanbanadaki H; Moradpour F; Eshrati B; Moradi G; Azami M; Haji Ghadery A; Mehrabi Nejad MM; Moradi Y Expert Rev Vaccines; 2022 Oct; 21(10):1455-1464. PubMed ID: 35830883 [TBL] [Abstract][Full Text] [Related]
52. Cerebral Venous Sinus Thrombosis and Thrombotic Events After Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis. Palaiodimou L; Stefanou MI; Katsanos AH; Aguiar de Sousa D; Coutinho JM; Lagiou P; Michopoulos I; Naska A; Giannopoulos S; Vadikolias K; Voumvourakis KI; Papaevangelou V; Vassilakopoulos TI; Tsiodras S; Tsivgoulis G Neurology; 2021 Nov; 97(21):e2136-e2147. PubMed ID: 34610990 [TBL] [Abstract][Full Text] [Related]
53. Breakthrough SARS-CoV-2 infections and prediction of moderate-to-severe outcomes during rituximab therapy in patients with rheumatic and musculoskeletal diseases in the UK: a single-centre cohort study. Md Yusof MY; Arnold J; Saleem B; Vandevelde C; Dass S; Savic S; Vital EM; Emery P Lancet Rheumatol; 2023 Feb; 5(2):e88-e98. PubMed ID: 36712951 [TBL] [Abstract][Full Text] [Related]
54. Immunogenicity and Risk Factors Associated With Poor Humoral Immune Response of SARS-CoV-2 Vaccines in Recipients of Solid Organ Transplant: A Systematic Review and Meta-Analysis. Manothummetha K; Chuleerarux N; Sanguankeo A; Kates OS; Hirankarn N; Thongkam A; Dioverti-Prono MV; Torvorapanit P; Langsiri N; Worasilchai N; Moonla C; Plongla R; Garneau WM; Chindamporn A; Nissaisorakarn P; Thaniyavarn T; Nematollahi S; Permpalung N JAMA Netw Open; 2022 Apr; 5(4):e226822. PubMed ID: 35412626 [TBL] [Abstract][Full Text] [Related]
55. Effectiveness of BNT162b2 Vaccine Booster against SARS-CoV-2 Infection and Breakthrough Complications, Israel. Glatman-Freedman A; Bromberg M; Hershkovitz Y; Sefty H; Kaufman Z; Dichtiar R; Keinan-Boker L Emerg Infect Dis; 2022 May; 28(5):948-956. PubMed ID: 35361311 [TBL] [Abstract][Full Text] [Related]
56. Effectiveness of mRNA and viral-vector vaccines in epidemic period led by different SARS-CoV-2 variants: A systematic review and meta-analysis. Zhang J; Yang W; Huang F; Zhang K J Med Virol; 2023 Mar; 95(3):e28623. PubMed ID: 36852651 [TBL] [Abstract][Full Text] [Related]
57. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021. Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519 [TBL] [Abstract][Full Text] [Related]
58. Physical interventions to interrupt or reduce the spread of respiratory viruses. Jefferson T; Dooley L; Ferroni E; Al-Ansary LA; van Driel ML; Bawazeer GA; Jones MA; Hoffmann TC; Clark J; Beller EM; Glasziou PP; Conly JM Cochrane Database Syst Rev; 2023 Jan; 1(1):CD006207. PubMed ID: 36715243 [TBL] [Abstract][Full Text] [Related]
59. Coronavirus Disease 19 (COVID-19) Vaccine Effectiveness Against Symptomatic Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection During Delta-Dominant and Omicron-Dominant Periods in Japan: A Multicenter Prospective Case-control Study (Factors Associated with SARS-CoV-2 Infection and the Effectiveness of COVID-19 Vaccines Study). Arashiro T; Arima Y; Muraoka H; Sato A; Oba K; Uehara Y; Arioka H; Yanai H; Kuramochi J; Ihara G; Chubachi K; Yanagisawa N; Nagura Y; Kato Y; Ueda A; Numata A; Kato H; Ishii K; Ooki T; Oka H; Nishida Y; Stucky A; Smith C; Hibberd M; Ariyoshi K; Suzuki M Clin Infect Dis; 2023 Feb; 76(3):e108-e115. PubMed ID: 35918782 [TBL] [Abstract][Full Text] [Related]
60. Vaccine effectiveness against SARS-CoV-2 infection or COVID-19 hospitalization with the Alpha, Delta, or Omicron SARS-CoV-2 variant: A nationwide Danish cohort study. Gram MA; Emborg HD; Schelde AB; Friis NU; Nielsen KF; Moustsen-Helms IR; Legarth R; Lam JUH; Chaine M; Malik AZ; Rasmussen M; Fonager J; Sieber RN; Stegger M; Ethelberg S; Valentiner-Branth P; Hansen CH PLoS Med; 2022 Sep; 19(9):e1003992. PubMed ID: 36048766 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]